Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.70
Ask: 3.90
Change: 0.00 (0.00%)
Spread: 0.20 (5.405%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.80
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Tan Delta revenue jumps; Kendrick Resources loss widens

Fri, 29th Sep 2023 21:19

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Tan Delta Systems PLC - Sheffield, England-based equipment monitoring and data analysis sensors maker - Reports revenue in the six months to June 30 increased by 54% to GBP0.96 million from GBP0.62 million the year prior. Pretax loss totalled GBP298,000 compared to pretax profit of GBP21,000. Basic and diluted loss per share was GBP0.01 against zero last year. Says revenue was primarily driven by a small number of prospects who commenced implementations following their evaluation period, and by a number of small sales to new customers commencing their evaluations. In the second half, expects more customers to enter and commence implementation on their equipment fleets, as well as contribution from our off the shelf SENSE-2 and MOT products.

----------

Oriole Resources PLC - London-based gold exploration company, focused on an early stage exploration project in Cameroon and Senala gold project in Senegal - Reports zero revenue in the six months to June 30, unchanged from the year prior. Administration expenses fell to GBP523,000 from GBP583,000 but pretax loss widened to GBP863,000 from GBP392,000. This reflected an adverse, non-cash foreign exchange loss on overseas assets. Basic loss per share totalled GBP0.03 versus zero the year before.

----------

CAP-XX Ltd - Sydney-based supercapacitor and energy management system manufacturer - Reports revenue in the year to June 30 of AUD3.6 million, down from AUD5.6 million the year prior. Pretax loss widened to GBP5.6 million from GBP4.9 million the year before and basic loss per share totalled 1.1 cents compared to 1.0c. Continues to pursue patent infringement action against Maxwell Technologies and other parties. Notes operating expenses were negatively impacted by AUD1.5 million of associated legal expenditure, down AUD1.0 million on prior year.

----------

Fusion Antibodies PLC - Belfast-based contract research organisation providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Reports revenue in the year to March 31 fell 40% to GBP2.9 million from GBP4.8 million the year before, while the pretax loss widened to GBP2.9 million from GBP1.3 million. Basic loss per share totalled 10.0 pence compared to 4.6p. Explains this year has been a tough year and very commercially challenging. The year has seen a downturn in market conditions and investment into customers' early-stage therapeutic pipelines Venture capital funding, typically the primary source of investment for early-stage biotech, has fallen to its lowest level since 2019. Says: "Whilst there remains a significant amount of uncertainty over the timing and implementation of future contract wins due to reduced investment in the broader biotech sector, we expect trading to recover incrementally over the short to medium term both in respect of existing services and the new services coming on stream."

----------

Kendrick Resources PLC - London-based Scandinavia-focused mineral exploration and development company - Reports zero income in the six months to June 30 compared to GBP10,872 the year prior. Pretax loss widened to GBP244,534 from GBP184,700 while basic loss per share totalled 0.10 pence compared to 0.24p. Says review of the company's projects gives confidence that "our north European assets are well located with significant potential in the quickly emerging space of energy generation and storage." Remains confident they have assembled an enviable portfolio of projects and look forward to advancing all projects in the second half of the year and providing shareholders with the prospects of enhanced value flowing into next year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Apr 2019 10:46

Fusion Antibodies revenues soar in strong second half

(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies reported a strong second half on Wednesday, driven by a significant increase in orders.

Read more
25 Feb 2019 11:56

Fusion Antibodies Guides For Revenue "Materially Below" Market Views

LONDON (Alliance News) - Fusion Antibodies PLC on Monday warned that annual revenue will be "materially below current market expectations" due to the uncertain timing of closure of were

Read more
25 Feb 2019 10:43

Fusion Antibodies dives as revenues falter

(Sharecast News) - Fusion Antibodies' shares plummeted on Monday after the company warned of failing revenues due to uncertainty surrounding the timing of "a number of potential substantial orders".

Read more
17 Dec 2018 14:51

Fusion Antibodies launches new 'RAMP' platform

(Sharecast News) - Pharmaceutical contract research organisation Fusion Antibodies launched its new 'Rational Affinity Maturation Platform' (RAMP) at the Antibody Engineering Conference in San Diego last week, it announced on Monday.

Read more
26 Nov 2018 10:39

Fusion Antibodies Interim Loss Widens On Increasing Competition

LONDON (Alliance News) - Fusion Antibodies PLC on Monday said that increasing competition, pricing pressures, and lower order levels have resulted in a substantial fall in revenue and a sharply of

Read more
26 Nov 2018 10:17

Fusion Antibodies sees losses widen throughout 'challenging' first half

(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies saw losses widen sharply throughout the first half of its trading year after revenues more than halved.

Read more
24 Sep 2018 17:03

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Buys Shares

LONDON (Alliance News) - Fusion Antibodies PLC said Monday Non-Executive Director Timothy Watts bought shares worth GBP10,237 in the life sciences firm in a transaction last Thursday.Watts

Read more
16 Aug 2018 13:40

Fusion Antibodies Posts Solid Revenue Rise But Warns On Current Trade

LONDON (Alliance News) - Fusion Antibodies PLC on Thursday said it has delivered strong annual revenue growth in a year in which it joined the London Stock Exchange's AIM market.The in

Read more
16 Aug 2018 08:10

Fusion Antibodies gets dragged to a loss as non-recurring items skyrocket

(Sharecast News) - Contract researcher Fusion Antibodies saw revenues hit £2.7m in its last trading year but was unable to chalk up a profit.

Read more
16 Aug 2018 08:10

Fusion Antibodies gets dragged to a loss as non-recurring items skyrocket

(Sharecast News) - Contract researcher Fusion Antibodies saw revenues hit £2.7m in its last trading year but was unable to chalk up a profit.

Read more
13 Aug 2018 10:31

WINNERS & LOSERS SUMMARY: Chemring Says Fatal Accident To Hurt Profit

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------BAE up 0.8%. a

Read more
13 Aug 2018 10:26

Fusion Antibodies Shares Fall 30% After Profit Warning For New Year

LONDON (Alliance News) - Shares fell in Fusion Antibodies PLC on Monday as it reported that trading in its current financial year to date has been slower than expected, due to increase competition

Read more
13 Aug 2018 08:27

Fusion Antibodies shares tumble following downbeat outlook

(Sharecast News) - Fusion Antibodies shares crashed on Monday morning after the Belfast-based researcher revealed that year-to-date trading had been "slower than anticipated".

Read more
24 May 2018 14:59

Fusion Antibodies Receives Up To GBP213,000 Grant From Invest NI

LONDON (Alliance News) - Fusion Antibodies PLC said Thursday it received additional grants from regional business development agency Invest Northern Ireland of up to GBP213,000.The company

Read more
4 Apr 2018 08:00

Qatar's market manipulation fears fuelled by "abnormal" derivative moves-bank CEO

* Qatar c. bank probing market manipulation during Gulf standoff * Qatar's top bank helping central bank with probe * QNB says has cash

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.